


Claims:

1. A compound of formula I,



- 5 wherein R¹ represents the non-hydroxy portion of a triazole antifungal compound of the type comprising a tertiary hydroxy group;
or a pharmaceutically acceptable salt thereof.

2. A compound as claimed in claim 1, wherein R¹ is a group of formula Ia,



- 10 in which

R² represents phenyl substituted by one or more halogen atoms;

R³ represents H or CH₃;

R^{3a} represents H, or together with R³ it may represent =CH₂; and

- 15 R⁴ represents a 5- or 6-membered nitrogen-containing heterocyclic ring which is optionally substituted by one or more groups selected from halogen, =O, phenyl [substituted by a group selected from CN and (C₆H₄)-OCH₂CF₂CHF₂] or CH=CH-(C₆H₄)-OCH₂CF₂CHF₂; or phenyl substituted by one or more groups selected from halogen and methylpyrazolyl.

3. A compound as claimed in claim 2, wherein R² is 2,4-difluorophenyl.

- 20 4. A compound as claimed in claim 2 or claim 3, wherein R³ is H or methyl.

5. A compound as claimed in any one of claims 2 to 4, wherein R⁴ represents or comprises a triazolyl, pyrimidinyl or thiazolyl group.

6. A compound as claimed in any one of the preceding claims, which is:

2-(2,4-difluorophenyl)-1,3-bis(1H-1,2,4-triazol-1-yl)-2-propyl dihydrogen phosphate; or

- 25 (2R,3S)-2-(2,4-difluorophenyl)-3-(5-fluoro-4-pyrimidinyl)-1-(1H-1,2,4-triazol-1-yl)-2-butyl dihydrogen phosphate;

or a pharmaceutically acceptable salt thereof.

7. A pharmaceutical formulation comprising a compound of formula I, as defined in claim 1, or a pharmaceutically acceptable salt thereof, in admixture with a
30 pharmaceutically acceptable adjuvant, diluent or carrier.

8. A compound of formula I, as defined in claim 1, or a pharmaceutically acceptable salt thereof, for use as a pharmaceutical.
9. The use of a compound of formula I, as defined in claim 1, or a pharmaceutically acceptable salt thereof, in the manufacture of a medicament for the treatment or prevention of fungal infections.
10. A method of treatment or prevention of fungal infections, which comprises administering a compound of formula I, as defined in claim 1, or a pharmaceutically acceptable salt thereof, to a patient in need of such treatment.
11. A process for the production of a compound of formula I, as defined in claim 1, or a pharmaceutically acceptable salt thereof, which comprises phosphorylating a compound of formula II,



wherein R^1 is as defined in claim 1;

and where desired or necessary converting the resulting compound into a pharmaceutically acceptable salt or vice versa.

12. A process as claimed in claim 11, which comprises the step of removing the hydroxy protecting groups from a compound of formula V,



wherein R^1 is as defined in claim 1, and R^c and R^d independently represent hydroxy protecting groups.

13. The process as claimed in claim 12, wherein R^c and R^d independently represent benzyl optionally substituted by one or more halogen atoms.
14. A compound of formula V, as defined in claim 12.
15. A method of improving the aqueous solubility of a triazole antifungal compound of the type comprising a tertiary hydroxy group, which comprises converting the tertiary hydroxy group into a phosphate group, or a pharmaceutically acceptable salt thereof.